Volitionrx (VNRX) Research & Development (2011 - 2025)

Volitionrx (VNRX) has 11 years of Research & Development data on file, last reported at $2.5 million in Q4 2025.

• For the quarter ending Q4 2025, Research & Development fell 4.61% year-over-year to $2.5 million; the trailing twelve-month figure through Dec 2025 stood at $10.1 million (down 30.02% YoY), and the FY2025 full-year result was $10.1 million, down 30.02% from the prior year.
• Research & Development for Q4 2025 stood at $2.5 million, up from $2.3 million in the prior quarter.
• Across five years, Research & Development topped out at $5.5 million in Q2 2023 and bottomed at $2.3 million in Q3 2025.
• The 5-year median for Research & Development is $3.6 million (2021), against an average of $3.6 million.
• The widest annual swing landed in 2023, when Research & Development soared 66.23%; it then tumbled 43.68% in 2025.
• A 5-year view of Research & Development shows it stood at $3.3 million in 2021, then climbed by 25.18% to $4.1 million in 2022, then gained by 10.02% to $4.5 million in 2023, then tumbled by 43.06% to $2.6 million in 2024, then retreated by 4.61% to $2.5 million in 2025.
• The last three Research & Development figures came in at $2.5 million (Q4 2025), $2.3 million (Q3 2025), and $2.7 million (Q2 2025), per Business Quant data.

Peer Comparison